	US 12,252,469 B2
	Crystalline forms of (E)-N-hydroxy-3-(1-(phenylsulfonyl)indolin-5-yl)acrylamide
Tsu-An Hsu, Taipei (TW); and Sue-Ming Chang, Taipei (TW)
Assigned to Chuan Shih, Taipei (TW); and ANBOGEN THERAPEUTICS INC., Taipei (TW)
Filed by ANBOGEN THERAPEUTICS INC., Taipei (TW)
Filed on Aug. 13, 2024, as Appl. No. 18/802,914.
Application 18/802,914 is a continuation of application No. 18/755,310, filed on Jun. 26, 2024.
Claims priority of provisional application 63/523,377, filed on Jun. 27, 2023.
Claims priority of provisional application 63/523,378, filed on Jun. 27, 2023.
Prior Publication US 2025/0011284 A1, Jan. 9, 2025
Int. Cl. C07D 209/30 (2006.01); A61K 9/48 (2006.01); A61K 31/4045 (2006.01)

CPC C07D 209/30 (2013.01) [A61K 9/4825 (2013.01); A61K 9/4858 (2013.01); A61K 9/4866 (2013.01); A61K 9/4875 (2013.01); A61K 31/4045 (2013.01)]

23 Claims

1. A crystalline form of (E)-N-hydroxy-3-(1-(phenylsulfonyl) indolin-5-yl) acrylamide (ABT-301), wherein the crystalline form comprises Type A form or Type B form; wherein Type A form is characterized by an X-ray powder diffraction pattern comprising peaks at 2θ values of 9.6±0.2, 15.1±0.2, 15.7±0.2, 16.7±0.2, 18.4±0.2°, 19.0±0.2 and 20.4±0.2; and

wherein Type B form is characterized by an X-ray powder diffraction pattern comprising peaks at 2θ values of 15.7±0.2, 16.6±0.2, 20.1±0.2 and 24.1±0.2.